Results 231 to 240 of about 242,673 (264)
Some of the next articles are maybe not open access.
Bioengineering factor Xa to treat bleeding
Thrombosis Research, 2016There is a clinical need to develop safe and rapid therapeutic strategies to control bleeding arising from a host of emergent situations. Over the past several years our laboratory has developed novel zymogen-like FXa variants and tested their safety and efficacy using hemophilia as a model system.
openaire +3 more sources
2023
This chapter describes factor Xa as a key enzyme involved in thrombosis and clot formation. It considers factor Xa inhibitors as potential anticoagulants for the treatment of deep-vein thrombosis and pulmonary embolism. It also highlights the first factor Xa inhibitors to reach the market and covers the design process that led to the discovery of ...
openaire +1 more source
This chapter describes factor Xa as a key enzyme involved in thrombosis and clot formation. It considers factor Xa inhibitors as potential anticoagulants for the treatment of deep-vein thrombosis and pulmonary embolism. It also highlights the first factor Xa inhibitors to reach the market and covers the design process that led to the discovery of ...
openaire +1 more source
Heparin-Binding Exosite of Factor Xa
Trends in Cardiovascular Medicine, 2000Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium ...
openaire +3 more sources
Inhibitors of Thrombin and Factor Xa
2000In medicine today, much effort is being made to develop new protease inhibitors for use as anticoagulants in multiple disease states. Deep venous thrombosis and pulmonary embolism, in particular, are major medical problems in the developed world. Similarly, myocardial infarction, stroke, and peripheral vascular disease are arterial thromboses for which
openaire +2 more sources
Factor‐Xa Inactivation by Antithrombin III
British Journal of Haematology, 1973Summary. The inactivation of the procoagulant activity of bovine factor Xa by antiproteinase present in antithrombin III preparation follows the pseudo‐first‐order kinetics with respect to factor Xa. The rate of inactivation is devoid of the dimension of factor Xa concentration when antiproteinase in excess is held constant.
openaire +3 more sources
Preservation of factor Xa activity
Thrombosis Research, 1978Van-Yu Wu, Walter H. Seegers
openaire +3 more sources
Current treatment and recent progress in gastric cancer
Ca-A Cancer Journal for Clinicians, 2021Smita S Joshi, Brian D Badgwell
exaly